RT Journal Article
SR Electronic
T1 Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.08.23289442
DO 10.1101/2023.05.08.23289442
A1 Omer Elneima
A1 Hamish J C McAuley
A1 Olivia C Leavy
A1 James D Chalmers
A1 Alex Horsley
A1 Ling-Pei Ho
A1 Michael Marks
A1 Krisnah Poinasamy
A1 Betty Raman
A1 Aarti Shikotra
A1 Amisha Singapuri
A1 Marco Sereno
A1 Victoria C Harris
A1 Linzy Houchen-Wolloff
A1 Ruth M Saunders
A1 Neil J Greening
A1 Matthew Richardson
A1 Jennifer K Quint
A1 Andrew Briggs
A1 Annemarie B Docherty
A1 Steven Kerr
A1 Ewen M Harrison
A1 Nazir I Lone
A1 Mathew Thorpe
A1 Liam G Heaney
A1 Keir E Lewis
A1 Raminder Aul
A1 Paul Beirne
A1 Charlotte E Bolton
A1 Jeremy S Brown
A1 Gourab Choudhury
A1 Nawar Diar Bakerly
A1 Nicholas Easom
A1 Carlos Echevarria
A1 Jonathan Fuld
A1 Nick Hart
A1 John R Hurst
A1 Mark G Jones
A1 Dhruv Parekh
A1 Paul Pfeffer
A1 Najib M Rahman
A1 Sarah L Rowland-Jones
A1 AA Roger Thompson
A1 Caroline Jolley
A1 Ajay M Shah
A1 Dan G Wootton
A1 Trudie Chalder
A1 Melanie J Davies
A1 Anthony De Soyza
A1 John R Geddes
A1 William Greenhalf
A1 Simon Heller
A1 Luke S Howard
A1 Joseph Jacob
A1 R Gisli Jenkins
A1 Janet M Lord
A1 William D-C Man
A1 Gerry P McCann
A1 Stefan Neubauer
A1 Peter JM Openshaw
A1 Joanna C Porter
A1 Matthew J Rowland
A1 Janet T Scott
A1 Malcolm G Semple
A1 Sally J Singh
A1 David C Thomas
A1 Mark Toshner
A1 Aziz Sheikh
A1 Christopher E Brightling
A1 Louise V Wain
A1 Rachael A Evans
A1 the PHOSP-COVID Collaborative Group
YR 2023
UL http://medrxiv.org/content/early/2023/05/11/2023.05.08.23289442.abstract
AB PHOSP-COVID is a national UK multi-centre cohort study of patients who were hospitalised for COVID-19 and subsequently discharged.PHOSP-COVID was established to investigate the medium- and long-term sequelae of severe COVID-19 requiring hospitalisation, understand the underlying mechanisms of these sequelae, evaluate the medium- and long-term effects of COVID-19 treatments, and to serve as a platform to enable future studies, including clinical trials.Data collected covered a wide range of physical measures, biological samples, and Patient Reported Outcome Measures (PROMs).Participants could join the cohort either in Tier 1 only with remote data collection using hospital records, a PROMs app and postal saliva sample for DNA, or in Tier 2 where they were invited to attend two specific research visits for further data collection and biological research sampling. These research visits occurred at five (range 2-7) months and 12 (range 10-14) months post-discharge. Participants could also participate in specific nested studies (Tier 3) at selected sites.All participants were asked to consent to further follow-up for 25 years via linkage to their electronic healthcare records and to be re-contacted for further research.In total, 7935 participants were recruited from 83 UK sites: 5238 to Tier 1 and 2697 to Tier 2, between August 2020 and March 2022.Cohort data are held in a Trusted Research Environment and samples stored in a central biobank. Data and samples can be accessed upon request and subject to approvals.Competing Interest StatementFull COI statement included in the submitted manuscript.Clinical Protocols https://www.phosp.org Funding StatementThis work was supported by a joint funding from the UK Research and Innovation and National Institute of Health Research [grant references: MR/V027859/1 and COV0319]. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Leeds West Research Ethics Committee (20/YH/0225) and is registered on the ISRCTN Registry (ISRCTN10980107).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe PHOSP-COVID study website (https://www.phosp.org) contains an overview of the study, resources, information about people involved, and publications. Research activity using the study is organised across a series of Working Groups (Figure 3). These were established at the outset of the study to coordinate research, minimise duplication of efforts, and facilitate communication across research and clinical specialties. Researchers interested in undertaking research using PHOSP-COVID are encouraged to contact the relevant Working Group leads (https://www.phosp.org/working-group/) in the first instance. The data are currently held in the Outbreak Data Analysis Platform (ODAP, https://odap.ac.uk/). Researchers seeking to access these data are directed to https://www.phosp.org/resource/ for information and forms. Correspondence to be directed to Dr Rachael A Evans, the Co-Principal Investigator of PHOSP-COVID study phosp{at}leicester.ac.uk. https://odap.ac.uk/